HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

Open Health Forum: more room for civil society?

Priorities of the Belgian Presidency

HAI Europe recommendations for improved conflict of interest declarations at EMA

International Experts Find that Pending Anti-Counterfeiting Trade Agreement Threatens Public Interests

ISDB & MiEF criticize EMA over conflict of interest procedures

Innovation & Access at the EU High Level Event on Global Health

Review of conflict of interest policies in three European medicines regulation agencies

Medicines manufacturers have clear motives for financing the patient voice

Quito Declaration

Independent drug bulletin and assessment reports from Spain – now in English

Quito Declaration

EU Global Health Council Conclusions presented at WHA

EU Ombudsman: Transparency rules apply to all documents held by EMA

Patient groups not only for sick people's interests – says Portuguese sociologist

Citizens call for inquiry into EU response to H1N1 outbreak

European Medicines Agency faces tough questions about patient groups' transparency

HAI hosts essay competition for students

EU-India negotiations on FTA pose a serious threat to access to affordable medicines in the developing world

Patient Groups need dose of transparency

EU lobby transparency book launch by ALTER-EU

LAC-EU Alliance for Access to Medicines welcomes compulsory license by Ecuadorian Government

Roundtable on ACTA by TACD

Generic prescribing policies 1 – ABPI 0

Snooping CEO unveils conflicts of interest at the European Medicines Agency

Where to find ACTA Draft Negotiating Text

EU Global Health Communication

Patient advocacy groups: another tool to boost compliance?

Finnish study: Drug companies see added value of patient group sponsorship

No NGO briefings will be allowed during World Health Assembly this year.